Semaglutide vs Liraglutide
Liraglutide (Saxenda) was the first GLP-1 widely used for weight loss; semaglutide (Wegovy) is the newer, weekly successor. Semaglutide generally wins on both weight loss and convenience — but liraglutide, now available as a generic, still has a role.
Last reviewed 2026-09-01 by the TopGLP1 Editorial Team
Educational, not medical advice. This page explains GLP-1 medications in general terms. Only a licensed clinician who knows your history can decide what's right for you.
Semaglutide wins for most people — more average weight loss and a once-weekly injection instead of daily. Liraglutide's edge is cost (generic) and availability.
Choose Semaglutide if…
you want more weight loss and the convenience of a weekly shot.
Choose Liraglutide if…
you want a lower-cost generic option or can't access weekly agents.
Side by side
| Semaglutide | Liraglutide | |
|---|---|---|
| Molecule | Semaglutide | Liraglutide |
| Dosing frequency | Once weekly | Once daily |
| Avg. weight loss | ~15% (STEP 1) | ~8% (SCALE) |
| Brand names | Wegovy, Ozempic | Saxenda, Victoza |
| Generic available | No | Yes (in some markets) |
| Approval | FDA-approved | FDA-approved |
How they compare on results
In trials, semaglutide 2.4 mg produced about 15% average weight loss (STEP 1) versus roughly 8% for liraglutide 3.0 mg (SCALE). Semaglutide is also once-weekly rather than a daily injection, which most people prefer.
Liraglutide's advantages are practical: it's older, well understood, and increasingly available as a lower-cost generic, making it a reasonable option when weekly agents are unavailable or unaffordable.
Side effects & safety
Similar GI side effects and the same class warnings. Liraglutide's daily dosing means some people experience side effects more constantly.
Cost
Branded Saxenda is expensive; generic liraglutide can be cheaper where available. Compounded semaglutide ($69/mo) is often the most affordable effective route overall.
Full drug guides
Semaglutide vs Liraglutide: common questions
Sources & references
Clinical figures on this page trace to peer-reviewed trials and official regulators. We link the primary record so you can verify it yourself.
- 1.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.Clinical trialNew England Journal of Medicine
- 2.Pi-Sunyer X, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22.Clinical trialNew England Journal of Medicine